Abstract: The present invention provides isolated, non-viable bacterial cells comprising a plurality of nucleic acid crosslinks, methods for making said cells, and methods for using said cells to isolate DNA-protein complexes. In particular, the nucleic acids of the cells are crosslinked by contacting the cells with a furocoumarin compound and ultraviolet light.
Type:
Grant
Filed:
September 2, 2011
Date of Patent:
June 6, 2017
Assignee:
SIGMA-ALDRICH CO., LLC
Inventors:
Vikas B. Palhan, Carol Kreader, Ernie Mueller
Abstract: The present disclosure provides genetically engineered cell lines comprising chromosomally integrated synthetic sequences having predetermined epigenetic modifications, wherein a predetermined epigenetic modification is correlated with a known diagnosis, prognosis or level of sensitivity to a disease treatment. Also provided are kits comprising said epigenetically modified synthetic nucleic acids or cells comprising said epigenetically modified synthetic nucleic acids that can be used as reference standards for predicting responsiveness to therapeutic treatments, diagnosing diseases, or predicting disease prognosis.
Abstract: A composition suitable for formulation of an enzymatic reaction mixture, the composition comprising a reaction component essential for an ex-vivo non-polymerase enzymatic reaction in which a substrate is catalyzed by an enzyme in a reaction mixture to form a product, and a tracer compatible with the enzyme, the composition being substantially free of the substrate.
Type:
Grant
Filed:
April 12, 2007
Date of Patent:
December 27, 2016
Assignee:
Sigma-Aldrich Co. LLC
Inventors:
Brian W. Ward, David M. Ornitz, Michael G. Deines, Thomas F. Bittick
Abstract: The present invention provides methods and kits for editing specific chromosomal sequences in cells. In particular, targeting endonucleases and single-stranded nucleic acids are used to edit the chromosomal sequence.
Type:
Grant
Filed:
July 22, 2011
Date of Patent:
December 6, 2016
Assignee:
Sigma-Aldrich Co. LLC
Inventors:
Fuqiang Chen, Shondra M. Pruett-Miller, Gregory D. Davis
Abstract: The present invention provides cell lines deficient in mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase I (Mgat1). Also provided are methods for producing the Mga1 deficient cell lines and methods for using the Mgat1 deficient cell lines for the production of recombinant proteins having simple glycoforms.
Type:
Grant
Filed:
January 10, 2013
Date of Patent:
June 28, 2016
Assignee:
SIGMA-ALDRICH CO. LLC
Inventors:
Nan Lin, Natalie Sealover, Henry George, Kevin Kayser
Abstract: The present disclosure encompasses an isolated cell comprising an exogenous nucleic acid sequence located within or proximal to a predetermined genomic locus, wherein the exogenous nucleic acid sequence comprises at least one recognition sequence which can be exploited by one or more polynucleotide modification enzymes for targeted integration of a recombinant protein. The disclosure further provides methods for preparing such cells, and methods for retargeting such cells for the production of recombinant proteins, and kits for the same.
Type:
Application
Filed:
June 19, 2014
Publication date:
May 26, 2016
Applicant:
Sigma-Aldrich Co. LLC
Inventors:
Scott BAHR, Trissa BORGSCHULTE, Kevin KAYSER
Abstract: A solid precursor delivery assembly generally includes a container having upper and lower portions and chambers defined within the container, including an inlet chamber, an outlet chamber, and first and second precursor chambers. The first and second precursor chambers are configured for holding precursor material within the container. Sintered frits are fixedly coupled and sealed to an interior portion of the container, and define at least part of the chambers within the container. At least one of the sintered frits is configured for retaining precursor material thereon within the first precursor chamber, and at least one of the sintered frits is configured for retaining precursor material thereon within the second precursor chamber. An inlet is coupled to the container for delivering carrier gas into the container, and an outlet is coupled to the container for use in removing vaporized precursor material and carrier gas from the container.
Type:
Grant
Filed:
October 21, 2010
Date of Patent:
March 29, 2016
Assignee:
SIGMA-ALDRICH CO. LLC
Inventors:
Ravi Kanjolia, Chris Platts, Nam Nguyen, Mark Wilkinson
Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
Type:
Application
Filed:
December 5, 2013
Publication date:
January 21, 2016
Applicant:
SIGMA-ALDRICH CO. LLC
Inventors:
Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
Abstract: Disclosed herein are methods and compositions for genome editing of one or more loci in a rat, using fusion proteins comprising a zinc-finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
Abstract: Molybdenum complexes and use thereof in thin film deposition, such as CVD and ALD are provided herein. The molybdenum complexes correspond in structure to Formula (I) and Formula (II), wherein R1, R3, R5, R7, R8 and R10 are independently and at each occurrence alkyl; R2, R6 and R9 are independently alkyl; R4 and R11 are independently and at each occurrence selected from the group consisting of alkyl, alkenyl, and alkynyl; x, z, a, c, d and f are independently zero, 1, or 2; y, b and e are independently zero or 1; and n and m are independently zero to 5.
Type:
Grant
Filed:
January 18, 2013
Date of Patent:
November 3, 2015
Assignee:
SIGMA-ALDRICH CO. LLC
Inventors:
Rajesh Odedra, Shaun Garratt, Mark Saly, Ravi Kanjolia
Abstract: This disclosure provides methods and devices for quantitating, separating and/or detecting water in a liquid, gas or solid sample comprising one or more chemicals, the method comprising: providing the liquid, gas or solid sample comprising water and the one or more chemicals; and exposing said liquid, gas or solid sample to at least one solid support including at least one dicationic and/or tricationic species of Formula I or II adsorbed, absorbed or immobilized on the solid support.
Abstract: The present invention provides methods for the rapid and efficient isolation of small RNA from a biological sample. In particular, small RNA is separated and isolated from large RNA, DNA, proteins, and other macromolecules in the biological sample.
Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
Type:
Grant
Filed:
January 30, 2015
Date of Patent:
June 23, 2015
Assignee:
SIGMA-ALDRICH CO. LLC
Inventors:
Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
Type:
Application
Filed:
January 30, 2015
Publication date:
June 4, 2015
Applicant:
SIGMA-ALDRICH CO. LLC
Inventors:
Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
Abstract: A method for forming a cobalt-containing thin film by a vapor deposition process is provided. The method comprises using at least one precursor corresponding in structure to Formula (I); wherein R1 and R2 are independently C2-C8-alkyl; x is zero, 1 or 2; and y is zero or 1; wherein both x and y can not be zero simultaneously.
Type:
Grant
Filed:
July 27, 2010
Date of Patent:
May 12, 2015
Assignee:
Sigma-Aldrich Co. LLC
Inventors:
Rajesh Odedra, Neil Boag, Jeff Anthis, Ravi Kanjolia
Abstract: The present disclosure provides compositions and methods for acetylating histones at targeted chromosomal locations in a cell. In particular, the disclosure provides a fusion protein comprising a DNA binding domain and at least one histone acetyltransferase (HAT) domain, such that the DNA binding domain targets the fusion protein to a targeted chromosomal location and the HAT domain acetylates histones at the targeted location.
Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
Type:
Grant
Filed:
June 29, 2012
Date of Patent:
March 17, 2015
Assignee:
Sigma-Aldrich Co. LLC
Inventors:
Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
Abstract: Organometallic complexes and use thereof in thin film deposition, such as CVD and ALD are provided herein. The organometallic complexes are (alkyl-substituted ?3-allyl)(carbonyl)metal complexes.
Type:
Grant
Filed:
August 8, 2012
Date of Patent:
January 6, 2015
Assignee:
Sigma-Aldrich Co. LLC
Inventors:
Rajesh Odedra, Neil Boag, Jeff Anthis, Ravi Kanjolia, Mark Saly